|
|
 |
 |
 |
|
|
|||
|
||||
|
||||
Re: GYN: New Blood Test for Ovarian Cancer?From: Dr. John Provatopoulos B.Sc. M.D.C.M. F.R.S.C. (johnprov@sympatico.ca)Fri Feb 15 05:22:10 2008
Here is the abstract of the paper to be published, note the cancer parients had already been diagnosed prior to taking the test, CA125 is still part of the screen, for now I just think this is heading to a much better way to monitor for response and reccurence than just CA125. There are thousands of women in the BRAC1&2 database if this screen actual picks up cancers in this sub group i will start getting impressed. A screening test always looks better and yes is more helpfull when the incidence of the illness in the study population is high, epidemiology 101.
> 1: Clin Cancer Res. 2008 Feb 7 Diagnostic Markers for Early Detection of Ovarian Cancer.Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, Tenthorey J, Leiser A, Flores-Saaib R, Yu H, Azori M, Rutherford T, Schwartz PE, Mor G. Departments of Obstetrics and Gynecology and Reproductive Science, Yale University School of Medicine, New Haven, Connecticut; Division of Public Health Science, Fred Hutchinson Cancer Research Center, Seattle, Washington; The Nevada Cancer Institute, Las Vegas, Nevada; Department of Statistics, The George Washington University, Washington, District of Columbia; Millipore Corporation, Temecula, California; and Departments of Epidemiology and Public Health and Obstetrics and Gynecology, Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut. PURPOSE: Early detection would significantly decrease the mortality rate of ovarian cancer. In this study, we characterize and validate the combination of six serum biomarkers that discriminate between disease-free and ovarian cancer patients with high efficiency.EXPERIMENTAL DESIGN: We analyzed 362 healthy controls and 156 newly diagnosed ovarian cancer patients. Concentrations of leptin, prolactin, osteopontin, insulin-like growth factor II, macrophage inhibitory factor, and CA-125 were determined using a multiplex, bead-based, immunoassay system. All six markers were evaluated in a training set (181 samples from the control group and 113 samples from OC patients) and a test set (181 sample control group and 43 ovarian cancer).RESULTS: Multiplex and ELISA exhibited the same pattern of expression for all the biomarkers. None of the biomarkers by themselves were good enough to differentiate healthy versus cancer cells. However, the combination of the six markers provided a better differentiation than CA-125. Four models with <2% classification error in training sets all had significant improvement (sensitivity 84%-98% at specificity 95%) over CA-125 (sensitivity 72% at specificity 95%) in the test set. The chosen model correctly classified 221 out of 224 specimens in the test set, with a classification accuracy of 98.7%.CONCLUSIONS: We describe the first blood biomarker test with a sensitivity of 95.3% and a specificity of 99.4% for the detection of ovarian cancer. Six markers provided a significant improvement over CA-125 alone for ovarian cancer detection. Validation was performed with a blinded cohort. This novel multiplex platform has the potential for efficient screening in patients who are at high risk for ovarian cancer. PMID: 18258665 [PubMed - as supplied by publisher]
--
Take care, John
|
|
Return to
|
Mail a New Message to the Forum: ob-gyn-l@obgyn.net Forum Administrator: geffrey.klein@obgyn.net Report Technical Problems: webmaster@obgyn.net Last Updated: Thu Oct 2 04:58:57 2008 |
The American Medical Association is no longer designating CME hours for AMA Category II CME credit. However, physicians themselves may self designate learning activities as Category II CME credit hours if they feel it is of sufficient educational merit and meets the formal definitions of continuing medical education. OBGYN.net believes these interaction in this forum meets these criteria. For further information see the AMA web site.